PubHawk
December 2007 PMID 17941858

Chronic high dose transdermal nicotine in Parkinson's disease: an open trial.

G Villafane, P Cesaro, A Rialland, S Baloul, S Azimi, C Bourdet, J Le Houezec, I Macquin-Mavier, P Maison

Download social card

Mentions

7
Peak: 1 in Jul 2014
across 3 sources since Jul 2014

Extended reach

3,703
potential audience

Total likes

6

Video views

356

Mentions per month

Jul 2014 – Mar 2025

Where it's discussed

  • News3 articles
  • X / Twitter2 posts
  • YouTube2 videos

AI synopsis

What people are saying

The posts reveal a mix of recognition of the research's relevance, such as the mention of nicotine's potential effects on Parkinson's symptoms, and personal stories like the comment about a family member with Parkinson's. The tone varies from supportive to anecdotal, highlighting interest but limited engagement with the study's scientific details or broader implications.

AgreementModerate agreement

Some posts express support, especially by noting the potential relevance of nicotine to Parkinson's treatment, but there's no widespread consensus.

InterestModerate interest

Discussions show moderate curiosity, with personal anecdotes and reflections but limited in-depth analysis.

EngagementNeutral engagement

Most posts offer brief comments or personal stories without deep exploration of the research details.

ImpactNeutral impact

The overall discussion doesn't suggest a transformative or widely influential impact, mostly sharing personal experiences and brief opinions.

Abstract in brief

  • This open-label trial investigated the safety and potential benefits of high-dose transdermal nicotine in six patients with advanced Parkinson's disease, finding it feasible to administer doses up to 105 mg/day over 17 weeks.
  • Patients experienced common but manageable side effects like nausea and vomiting, especially at higher doses, but most tolerated the treatment well.
  • Patients showed improvements in motor symptoms during the treatment phase, and their need for dopaminergic medication was reduced, suggesting potential therapeutic effects that should be further studied through controlled trials.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Gerard Hough
@GerardHough · X

https://t.co/RgkZzRMkJL Chronic high dose transdermal nicotine in Parkinson's disease: an open trial 2007

Jul 15, 2023 · 1,755 followers View post →
Southernvaper
@Southernvaper1 · X

@SeismicPirate My mom lived with Parkinsons for aprox 25yrs. Her Dr's told me because she never used nic a lower dose would work for her. As her symptoms grew she would need more. Dr's went on to say if a smoker they would start them with more nic. https://t.co/Dc4wnZXICD

May 22, 2022 · 1,593 followers View post →

All mentions

Gerard Hough
@GerardHough · X

https://t.co/RgkZzRMkJL Chronic high dose transdermal nicotine in Parkinson's disease: an open trial 2007

Jul 15, 2023 · 1,755 followers View post →
Southernvaper
@Southernvaper1 · X

@SeismicPirate My mom lived with Parkinsons for aprox 25yrs. Her Dr's told me because she never used nic a lower dose would work for her. As her symptoms grew she would need more. Dr's went on to say if a smoker they would start them with more nic. https://t.co/Dc4wnZXICD

May 22, 2022 · 1,593 followers View post →